Shares of Haemonetics Corporation (NYSE:HAE) have earned an average rating of “Hold” from the eight analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $51.20.

HAE has been the topic of several recent research reports. Zacks Investment Research downgraded Haemonetics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 16th. Morgan Stanley restated an “equal weight” rating and issued a $43.00 price target (up previously from $38.00) on shares of Haemonetics in a research note on Friday, October 6th. Barrington Research upped their price target on Haemonetics from $48.00 to $57.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 8th. Finally, Craig Hallum restated a “hold” rating and issued a $50.00 price target (up previously from $40.00) on shares of Haemonetics in a research note on Wednesday, November 8th.

In other Haemonetics news, CAO Dan Goldstein sold 4,691 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $54.93, for a total transaction of $257,676.63. Following the sale, the chief accounting officer now directly owns 3,747 shares in the company, valued at approximately $205,822.71. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Willaim P. Burke sold 13,193 shares of the stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $54.04, for a total value of $712,949.72. Following the sale, the chief financial officer now owns 27,227 shares in the company, valued at $1,471,347.08. The disclosure for this sale can be found here. Insiders sold a total of 47,368 shares of company stock worth $2,602,393 in the last 90 days. 1.20% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. US Bancorp DE boosted its stake in Haemonetics by 0.6% during the 2nd quarter. US Bancorp DE now owns 22,154 shares of the medical instruments supplier’s stock valued at $875,000 after purchasing an additional 141 shares during the last quarter. Tudor Investment Corp ET AL boosted its stake in Haemonetics by 0.5% during the 2nd quarter. Tudor Investment Corp ET AL now owns 28,126 shares of the medical instruments supplier’s stock valued at $1,111,000 after purchasing an additional 143 shares during the last quarter. Strs Ohio boosted its stake in Haemonetics by 1.0% during the 2nd quarter. Strs Ohio now owns 29,300 shares of the medical instruments supplier’s stock valued at $1,157,000 after purchasing an additional 300 shares during the last quarter. Arizona State Retirement System boosted its stake in Haemonetics by 1.1% during the 2nd quarter. Arizona State Retirement System now owns 27,397 shares of the medical instruments supplier’s stock valued at $1,082,000 after purchasing an additional 300 shares during the last quarter. Finally, Amalgamated Bank boosted its stake in Haemonetics by 5.7% during the 2nd quarter. Amalgamated Bank now owns 7,322 shares of the medical instruments supplier’s stock valued at $289,000 after purchasing an additional 392 shares during the last quarter.

Haemonetics (NYSE:HAE) opened at $56.56 on Friday. The company has a current ratio of 2.17, a quick ratio of 1.51 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $3,029.65, a P/E ratio of 35.19, a price-to-earnings-growth ratio of 4.31 and a beta of 0.99. Haemonetics has a twelve month low of $36.44 and a twelve month high of $58.99.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.07. The company had revenue of $225.40 million for the quarter, compared to the consensus estimate of $219.12 million. Haemonetics had a return on equity of 11.16% and a net margin of 0.50%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.38 EPS. sell-side analysts expect that Haemonetics will post 1.7 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/08/haemonetics-corporation-hae-given-consensus-rating-of-hold-by-analysts.html.

Haemonetics Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Analyst Recommendations for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.